Articles tagged with Alzheimer Disease
A study by TGen suggests that increasing ABCC1 expression could reduce Abeta production, preventing or delaying the onset of Alzheimer's. The gene modulates cellular processes involving amyloid precursor protein, potentially reducing plaque formation and cognitive decline.
A new study reveals a potential mechanism linking traumatic brain injury (TBI) and Alzheimer's disease (AD), as well as a method for preventing nerve cell degeneration after injury. Researchers discovered a blood biomarker of neurodegeneration that could stage severity and progression of TBI-induced nerve cell deterioration.
A study by NYU College of Dentistry and Weill Cornell Medicine found that older adults with more harmful than healthy bacteria in their gums are more likely to have evidence for amyloid beta, a key biomarker for Alzheimer's disease. The researchers suggest that high levels of 'good' bacteria may be protective against Alzheimer's.
The expanded patient-level data will facilitate more efficient clinical trial design, enabling generation of novel drug development tools and solutions. The novel tools and solutions will enable better informed inclusion criteria, endpoint selection, and patient enrichment strategies.
A recent study has discovered a profound loss of ability to experience pleasure in people with early-onset dementia, known as frontotemporal dementia (FTD). Grey matter deterioration in the 'pleasure system' of the brain was found, distinct from those implicated in depression or apathy.
A rare PLD3 mutation in Alzheimer's patients disrupts lysosomal recycling, leading to fewer β-amyloid plaques and less cognitive decline. Boosting PLD3 may have a protective effect against the disease.
A study published in Alzheimer's & Dementia found that progressive memory loss and issues with executive function are more useful for predicting CTE pathology than mood and behavior symptoms. This breakthrough could lead to the development of new therapies and improved patient care.
The University of South Florida has received a five-year, $44.4 million NIH grant to conduct the largest primary prevention trial of computer-based cognitive training for preventing mild cognitive impairment and dementias like Alzheimer's disease in older adults. The study aims to test whether this type of training can reduce the risk ...
A USC study projects significant savings for US state Medicaid programs if treatments helping patients with Alzheimer's disease live independently longer are introduced. The study forecasts annual savings of $7.4 billion in 2030 and over $22 billion by 2040, preventing over one million patient-years of nursing home use.
A novel mechanism has been identified that might explain why a rare mutation is associated with familial Alzheimer's disease. The presence of the S198P mutation resulted in elevated levels of A? peptides due to rapid folding of APP, leading to faster production and deposition of A? peptides.
A study has identified 13 rare gene variants associated with Alzheimer's disease, which are linked to the functioning of synapses and neuroplasticity. These discoveries could help guide the development of new therapies for this devastating neurological condition.
Researchers explored how molecular changes in Alzheimer's patients relate to brain function, developed a new model for predicting life expectancy of older adults with multiple chronic diseases, and examined older firearm owners' perspectives on retiring their guns.
A new study by Brigham Young University researchers found widespread glucose metabolism impairment in Alzheimer's Disease brains, while ketolytic metabolism remained relatively intact. The study proposes that dietary and lifestyle changes could slow cognitive decline associated with the disease.
A new study published in Neurology shows that cholinesterase inhibitors can slow cognitive decline and reduce mortality in people with Alzheimer's disease. The study found that patients treated with these drugs had a 27% lower risk of death compared to those not treated, highlighting the benefits of current treatment recommendations.
A new approach has led to the discovery of a small molecule that may help regulate cholesterol levels in the brain, making it a potential therapeutic target for Alzheimer's disease. Increasing the activity of ABCA1 is expected to positively influence insulin signaling and reduce inflammation in the brain.
Research from Lund University in Sweden suggests that women accumulate Alzheimer's-related protein tau at a higher rate than men. The study found a 75% higher accumulation rate of tau in women compared to men in the temporal lobe affected by the disease.
Persistent midlife loneliness is linked to a higher risk of developing dementia and Alzheimer's disease, while transient loneliness may actually reduce the risk. Researchers found that recovering from loneliness after 18 years may also lead to lower risk of dementia onset.
Researchers have identified BMI1 as a key player in protecting neurons from DNA disorganization, a phenomenon associated with Alzheimer's disease. The discovery adds to our understanding of the fundamental mechanisms leading to the disorder and brings hope for future treatments.
A new gene regulation therapy using zinc finger proteins has shown high efficacy in reducing Tau protein levels in the brain, potentially protecting against Alzheimer's disease. The treatment reduces Tau production by 50-80% and prevents nerve damage without obvious side effects.
A new gene therapy approach using zinc finger proteins has shown long-lasting effects in reducing tau protein levels and reversing brain damage in an animal model of Alzheimer's disease. The treatment involves a single injection and could potentially lead to a new treatment for patients with this devastating illness.
A recent review of 150 articles suggests that a small leak in the blood-brain barrier is associated with benign forgetfulness of aging, which could be an early stage of Alzheimer's disease. Researchers also found that preserving pericyte function may lead to a healthier blood-brain barrier and potentially treat Alzheimer's.
Researchers have developed a new animal model of early-stage Alzheimer's disease in rhesus macaques, which could enable better testing of new treatments. The model replicates the spread of misfolded tau proteins through brain circuits, similar to human disease progression.
Researchers found that brain diseases like Alzheimer's and Parkinson's affect men and women differently. The study suggests that accounting for sex differences in research leads to better results.
The study uses a generative adversarial network to classify Alzheimer's disease with improved accuracy. The model learns from low- and high-quality brain images, generating images of better quality that predict disease status more accurately than traditional models.
A recent study published in Annals of Clinical and Translational Neurology found that head injuries in people under 50 can lead to lower cognitive scores at age 70. The researchers discovered a small but significant impact on brain health and thinking skills, potentially accelerating the normal aging process.
A new study reveals a close link between proteins causing Alzheimer's disease and age-related sight loss, with findings showing toxic molecules accumulate in retina cells. The research also suggests that anti-amyloid beta drugs may be repurposed to treat age-related macular degeneration.
A comprehensive mutation map of the amyloid beta peptide has been developed to predict whether specific mutations increase an individual's risk of developing Alzheimer's disease. The study found that certain mutations accelerate protein aggregation, leading to the formation of toxic plaques in the brain.
Scientists have developed a tool to monitor brain communications, offering an explanation for why Alzheimer's drugs are ineffective. The new method has broad applicability across neurological and psychiatric diseases, facilitating the development of new treatments and personalized medicine.
A team at Massachusetts General Hospital developed an artificial intelligence-based method to screen currently available medications as possible treatments for Alzheimer's disease. The analysis yielded a ranked list of candidates, including anti-inflammatory drugs used to treat rheumatoid arthritis and blood cancers.
A recent study by Berkeley Lab scientists confirms the hypothesis that a protein called ORF8 holds the answer to understanding how the new strain of coronavirus evolved. Meanwhile, a new report assesses the economic costs of widespread power outages and finds that utilities rarely account for direct and indirect costs.
A study from MIT reveals the APOE4 gene variant causes widespread disruptions in brain cells' ability to metabolize lipids and respond to stress. Supplementing with choline may reverse these effects, offering a potential new approach to treating Alzheimer's disease.
Researchers identified a new drug that modulates a key enzyme to prevent amyloid plaque formation, reducing or eliminating problematic protein fragments. The novel compound showed safety and effectiveness in rodent and monkey studies, suggesting potential as a therapy for Alzheimer's disease.
A new drug has been identified that can prevent Alzheimer's disease by modulating the enzyme involved in forming amyloid plaques. The drug was tested on rodents and monkeys, demonstrating safety and effectiveness in reducing Aβ42 production and plaque formation.
Researchers found that heart failure causes impaired gene activity in the brain's memory center, leading to cognitive deficits. A specific drug alleviated mental deficits in mice, suggesting potential approaches for therapies.
Researchers found that curcumin intake increases ApoA-II and HDL-cholesterol concentrations by activating the PPARα signaling pathway, leading to increased AApoAII amyloid deposition. This discovery provides a novel molecular target for understanding amyloidogenesis and treating metabolic disorders.
Researchers have developed a new technique using bowl-shaped nanoparticles to study Alzheimer's disease amyloid beta protein aggregates. The findings confirm multiple forms of these aggregates co-exist and not all convert into brain plaques, opening possibilities for diagnostic and treatment applications.
Researchers at OHSU discovered a correlation between gut microbiome composition and cognitive performance in mice with genes associated with Alzheimer's. The study suggests a relationship between microbes and epigenetic changes in the brain, potentially leading to new treatments for Alzheimer's.
A new radiology research study suggests that focused ultrasound treatment may induce an immunological healing response in Alzheimer's patients, and open the blood-brain barrier. The treatment targets the hippocampus, which plays a large role in learning and memory.
Researchers identified two new genes linked to Alzheimer's disease, PTPN9 and PCDHA4, in a study of gene expression in the hippocampus. The findings suggest that these genes contribute to the progression of the disease through pathways related to plaque formation and cell death.
A new study identifies a potential link between blast exposure and Alzheimer's disease in soldiers. Researchers found that even healthy neurons with subtle synaptic pathology may be an early indicator of Alzheimer's-type pathogenesis.
A study published in Neuropathology and Applied Neurobiology reveals that RAPGEF2 protein overexpression leads to synaptic damage and cognitive impairment in Alzheimer's disease. Silencing RAPGEF2 prevents synapse loss and cognitive decline, suggesting a potential therapeutic target for neurodegenerative diseases.
A new study found that people with depression and anxiety may experience dementia symptoms about two years earlier than those without these conditions. Those with bipolar disorder or schizophrenia may start experiencing symptoms three to seven years earlier.
Tau oligomers form droplets within TIA1 droplets selectively, producing highly lethal effects on neurons. The study provides a tool to screen compounds that can inhibit tau oligomer formation, offering hope for Alzheimer's and frontotemporal dementia treatment.
Researchers found reduced functional connectivity between brain regions in people with HIV and APOE4, leading to poorer memory function. Severe immunosuppression further exacerbated the impact of APOE4 on memory performance.
Researchers discovered white matter hyperintensities are more common and severe in people with frontotemporal dementia compared to Alzheimer's disease and healthy controls. The study suggests these changes contribute to cognitive problems rather than vascular factors.
A unique brain protein measured in the blood could be used to diagnose Alzheimer's disease decades before symptoms develop. Elevated glial fibrillary acidic protein (GFAP) levels in the blood are associated with increased amyloid beta in the brain, a known indicator of Alzheimer's disease.
Researchers found that cognitive SuperAgers have fewer tau protein tangles in the brain region related to memory, which may contribute to their preserved memory capacity. The study suggests a potential new direction for Alzheimer's disease research and highlights the importance of understanding the cellular mechanisms behind SuperAging.
A genetic study of Lewy body dementia suggests that the disease is caused by a spectrum of problems seen in both Alzheimer's and Parkinson's diseases. Five genes have been identified as critical to the development of Lewy body dementia, with variations in these genes also linked to increased risk of Alzheimer's and Parkinson's diseases.
A new study from the University of Eastern Finland found that people with Alzheimer's disease (AD) had a higher risk of mortality in procedural units and during follow-up, compared to those without AD. However, elective revascularisation procedures showed similar outcomes for both groups.
A study from Duke University Medical Center found that individuals with an APOE4 gene variant associated with increased Alzheimer's risk have lower levels of inflammatory molecules in their cerebrospinal fluid, suggesting potential damage to synapses.
Metal-containing diagnostic agents can detect early AD markers and synchrotron-independent, long-lived. They may improve access to AD imaging for risk groups, offering a solution to the current limitations of PET, MRI, and SPECT imaging.
A study found patients with dementia twice as likely to contract COVID-19 and experience worse outcomes. African Americans with dementia faced a near-threefold higher risk of infection. The researchers emphasized the need for strategies balancing safety from COVID-19 with protection from social isolation and health-related harms.
A new study by USask researchers found that a shorter form of a brain protein, Aβ38, halts damage-causing mechanisms of its longer counterpart, Aβ42. This discovery could help identify people at highest risk for developing Alzheimer's and slow or prevent its onset.
A study found that higher blood pressure at night than day increases the risk of Alzheimer's disease in older men. Researchers analyzed data from 1,000 Swedish men and found a 64% increased risk of dementia diagnosis among those with reverse dipping blood pressure patterns.
A $5 million grant will support studies on scalable, low-cost, and noninvasive approaches to identify Alzheimer's disease. The project aims to improve the quality of life for patients and families by providing validated tools for early detection.
A new study in mice restores normal protein synthesis to repair memory function, suggesting a potential means to address the loss of cognitive function due to Alzheimer's disease. Researchers found that administering synthetic pharmaceuticals, such as ISRIB, can revive lost cognitive functions and restore synaptic plasticity.
NeuroVision Imaging, Inc. has received an investment from the Alzheimer's Drug Discovery Foundation (ADDF) to develop reliable and affordable biomarker tests for Alzheimer's disease and related dementias. The goal is to improve clinical trials and monitor response to treatments.
Researchers developed an automated method to identify and track tau deposits in the brain, which may lead to earlier diagnoses of Alzheimer's disease. The technique revealed that tau deposits first emerge in the rhinal cortex region before spreading to other brain regions.
A new five-year study tests the effect of home-based indoor cycling on slowing Alzheimer's disease progression in healthy older individuals at high genetic risk. The study aims to enroll 150 participants and assess the impact of high-intensity interval training on brain regions critical to memory function.
Researchers at INRS have discovered two early plasma markers that can detect Alzheimer's disease five years before its onset, enabling earlier intervention. The study found that these markers are present in plasma extracellular vesicles and can be analyzed through a blood test, opening up new possibilities for studying the disease.